Expertise in
12
conditions

Dr. Anthony Evans

Oncology
MCHS Hospitals Inc.
1000 N Oak Ave, 
Marshfield, WI 
Expertise in
12
conditions
MCHS Hospitals Inc.
1000 N Oak Ave, 
Marshfield, WI 

Overview

Anthony Evans is an Oncologist practicing medicine in Marshfield, Wisconsin.

Dr. Evans is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Hernia Surgery, and Oophorectomy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in LA

Hospital Affiliations

Gundersen Lutheran Medical Center
Womans Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MCHS Hospitals Inc.
1000 N Oak Ave, Marshfield, WI 54449
Other Locations
John A. Dean MD A Medical Corp.
500 Rue De La Vie St Ste 410, Baton Rouge, LA 70817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
View 4 Less Clinical Trials

1 Total Publications

Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
Journal: Gynecologic oncology
Published: March 06, 2018
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Marshfield Medical Center-Marshfield Medical Offices Cancer Care

1000 N Oak Ave, 
Marshfield, WI 
 (80.7 miles away)
715-387-5416
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Seth Fagbemi is an Oncologist practicing medicine in Marshfield, Wisconsin. He has been practicing medicine for over 44 years. Dr. Fagbemi is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Familial Colorectal Cancer, WT1-Related Wilms Tumor Syndromes, Bone Marrow Transplant, and Prostatectomy.

Expertise in
62
conditions
Expertise in
62
conditions
Referral may be required

Marshfield Medical Center-Weston Medical Offices-Cancer Care

3400 Ministry Pkwy, 
Weston, WI 
 (111.8 miles away)
715-393-1400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adedayo Onitilo is an Oncologist practicing medicine in Weston, Wisconsin. Dr. Onitilo is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Breast Cancer, Colorectal Cancer, Pancreaticoduodenectomy, and Gallbladder Removal.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Marshfield Medical Center-Marshfield Medical Offices Cancer Care

1000 N Oak Ave, 
Marshfield, WI 
 (80.7 miles away)
715-387-5416
Languages Spoken:
English
See accepted insurances

Isaac Yeboah is an Oncologist practicing medicine in Marshfield, Wisconsin. Dr. Yeboah is highly rated in 24 conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Angiosarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Anthony Evans

How do I make an appointment with Dr. Anthony Evans?

You can book an appointment with Dr. Anthony Evans by calling their office at 715-387-5161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony Evans a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony Evans is classified as an Advanced expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony Evans specialize in?

While Dr. Anthony Evans is a Oncology, they have specific expertise in Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Endometrial Stromal Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anthony Evans participate in research or clinical trials?

Yes. Dr. Anthony Evans has published 1 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Anthony Evans's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony Evans accept my insurance?

Dr. Anthony Evans accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 715-387-5161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Evans's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 20 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile